Artificial Intelligence in Retina: Predicting nAMD Conversion Biomarkers Now and Future Potential

Hyperreflective foci volume, inner retinal thickness, retinal pigment epithelium to drusen complex thickness, and presence of subretinal drusenoid deposits stand out as significant predictors of conversion to nAMD

By: David A. Eichenbaum, MD, Michael A. Singer, MD

Retinal Physician October 23, 2025

5 Key Takeaways

1

Hyperreflective foci volume and subretinal drusenoid deposits are significant predictors of conversion to neovascular AMD (nAMD).
2

The Amaros Evidence Engine harmonizes data from various imaging and electronic health record platforms to analyze multiple biomarkers.
3

The study analyzed images from 90 retina clinics, focusing on 10,000 trial-eligible eyes with geographic atrophy (GA).
4

Four biomarkers were identified as significant predictors of nAMD conversion, while GA size and certain drusen types were not predictive.
5

AI can enhance clinical trial populations by identifying high-risk patients for conversion to nAMD, potentially revitalizing previously discarded therapies.

David A. Eichenbaum, MD

Director of Research

Affiliations: Retina Vitreous Associates of Florida

Specialties: Ophthalmology

Bio: David A. Eichenbaum, MD, FASRS, is director of research at Retina Vitreous Associates of Florida and collaborative associate professor at Morsani College of Medicine, University of South Florida, in Tampa, Florida. He is a retina specialist whose clinical trial work focuses on common retinal diseases including dry and wet age-related macular degeneration, diabetic eye disease, and retinal vascular disease. Dr. Eichenbaum has been a clinical trial investigator for 16 years and has participated in more than 90 trials. He is a Fellow of the American Society of Retina Specialists and the American Academy of Ophthalmology, immediate past president and board member of the Florida Society of Ophthalmology, and past president of the Tampa Bay Ophthalmic Society.

Michael A. Singer

Specialties: Ophthalmology

Bio: Michael A. Singer, MD, is a physician author covering retina topics for Retinal Physician. In a 2025 Retina Minute article, he discussed low-dose 0.01% atropine as a nonsurgical potential treatment for symptomatic vitreous floaters, including patient selection considerations and the importance of peripheral retinal examination before prescribing.

PentaVision

Retinal Physician

Artificial Intelligence in Retina: Predicting nAMD Conversion Biomarkers Now and Future Potential

5 Key Takeaways

1

2

3

4

5

Recommendations